marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q2
added 08-13-2024
TRACON Pharmaceuticals Balance Sheet 2011-2024 | TCON
Annual Balance Sheet TRACON Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | - | -11.1 M | -18.7 M | -22 M | -28.2 M | -32.5 M | -26.1 M | 165 K | -2.46 M | - |
Long Term Debt |
- | - | - | - | 2.74 M | 5.34 M | 4.6 M | 7.13 M | 7.46 M | 4.26 M | 1.76 M | - | - |
Long Term Debt Current |
- | 9.81 M | 1.39 M | 2.72 M | 2.6 M | 1.08 M | 2.84 M | 333 K | 1.38 M | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 3.59 M | 5.71 M | 7.34 M | 7.15 M | 8.37 M | 57.1 M | 25.7 M | 19.6 M | - |
Total Current Liabilities |
10.2 M | 22.4 M | 13.7 M | 10.5 M | 11.8 M | 13.5 M | 11.8 M | 10.2 M | 14.2 M | - | - | - | - |
Total Liabilities |
- | - | - | - | 15.4 M | 19.2 M | 19.1 M | 17.4 M | 22.5 M | 70.3 M | 27.8 M | 20.3 M | - |
Deferred Revenue |
- | - | - | - | - | - | 667 K | 1.26 M | 3.35 M | 4.36 M | - | - | - |
Retained Earnings |
-240 M | -237 M | -208 M | - | -162 M | -140 M | -105 M | -85.6 M | -58.6 M | -34.2 M | -27.4 M | -19.7 M | - |
Total Assets |
10.1 M | 19.5 M | 26.6 M | 37.4 M | 18.1 M | 40.6 M | 36.1 M | 45.7 M | 53.5 M | 38.2 M | 2.42 M | 2.61 M | - |
Cash and Cash Equivalents |
8.56 M | 17.4 M | 24.1 M | 32.1 M | 16.4 M | 25.1 M | 29.5 M | 35.7 M | 41.4 M | 35 M | 2.28 M | - | - |
Book Value |
10.1 M | 19.5 M | 26.6 M | 37.4 M | 2.7 M | 21.4 M | 17 M | 28.3 M | 31 M | -32.2 M | -25.3 M | -17.7 M | - |
Total Shareholders Equity |
-809 K | -7.15 M | 11.7 M | 25.1 M | 2.7 M | 21.4 M | 17 M | 28.3 M | 31 M | -32.2 M | -25.3 M | - | - |
All numbers in USD currency
Quarterly Balance Sheet TRACON Pharmaceuticals
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | 9.1 M | - | - | - | - | - | 698 K | 1.39 M | 1.39 M | 1.39 M | 1.39 M | 2.74 M | 2.74 M | 2.74 M | 2.74 M | 5.34 M | 5.34 M | 5.34 M | 5.34 M | 4.6 M | 4.6 M | 4.6 M | 4.6 M | 7.13 M | 7.13 M | 7.13 M | 7.13 M | 7.46 M | 7.46 M | 7.46 M | 7.46 M | 4.26 M | 4.26 M | 4.26 M | 4.26 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 667 K | 667 K | 386 K | 667 K | 1.26 M | 1.26 M | 1.26 M | 1.26 M | 3.35 M | 3.35 M | 3.35 M | 3.35 M | 4.36 M | 4.36 M | 4.36 M | 4.36 M | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-247 M | -244 M | -240 M | -241 M | -252 M | -245 M | -237 M | -230 M | -223 M | -217 M | -208 M | -200 M | -193 M | -184 M | -179 M | -179 M | -179 M | -179 M | -162 M | -162 M | -162 M | -162 M | -140 M | -140 M | -140 M | -140 M | -105 M | -105 M | -105 M | -105 M | -85.6 M | -85.6 M | -85.6 M | -85.6 M | -58.6 M | -58.6 M | -58.6 M | -58.6 M | -34.2 M | -34.2 M | -34.2 M | -34.2 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
7.4 M | 9.36 M | 10.1 M | 9.41 M | 12.2 M | 8.32 M | 19.5 M | 19.7 M | 15.7 M | 18.9 M | 26.6 M | 32.8 M | 26.8 M | 31.7 M | 37.4 M | 37.4 M | 37.4 M | 37.4 M | 18.1 M | 18.1 M | 18.1 M | 18.1 M | 40.6 M | 40.6 M | 40.6 M | 40.6 M | 36.1 M | 36.1 M | 36.1 M | 36.1 M | 45.7 M | 45.7 M | 45.7 M | 45.7 M | 53.5 M | 53.5 M | 53.5 M | 53.5 M | 38.2 M | 38.2 M | 38.2 M | 38.2 M | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
6.27 M | 7.89 M | 8.56 M | 7.76 M | 1.87 M | 6.68 M | 17.4 M | 17.2 M | 13.6 M | 16.6 M | 24.1 M | 29.9 M | 25.6 M | 26.4 M | 32.1 M | 32.1 M | 32.1 M | 32.1 M | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 25.1 M | 25.1 M | 25.1 M | 25.1 M | 29.5 M | 29.5 M | 29.5 M | 29.5 M | 35.7 M | 35.7 M | 35.7 M | 35.7 M | 41.4 M | 41.4 M | 41.4 M | 41.4 M | 35 M | 35 M | 35 M | 35 M | 2.28 M | - | - | - | 2.46 M | - | - | - | - | - | - | - |
Book Value |
7.4 M | 9.36 M | 10.1 M | 9.41 M | 12.2 M | 8.32 M | 19.5 M | 19.7 M | 15.7 M | 18.9 M | 26.6 M | 32.8 M | 26.8 M | 31.7 M | 37.4 M | 37.4 M | 37.4 M | 37.4 M | 18.1 M | 18.1 M | 18.1 M | 18.1 M | 40.6 M | 40.6 M | 40.6 M | 40.6 M | 36.1 M | 36.1 M | 36.1 M | 36.1 M | 45.7 M | 45.7 M | 45.7 M | 45.7 M | 53.5 M | 53.5 M | 53.5 M | 53.5 M | 38.2 M | 38.2 M | 38.2 M | 38.2 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-3.09 M | -1.76 M | -809 K | -3.08 M | -15.7 M | -11.1 M | -7.15 M | -2.64 M | -2.54 M | 2.79 M | 11.7 M | 18.9 M | 11.9 M | 20.4 M | 25.1 M | 25.1 M | 25.1 M | 25.1 M | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 21.4 M | 21.4 M | 21.4 M | 21.4 M | 17 M | 17 M | 17 M | 17 M | 28.3 M | 28.3 M | 28.3 M | 28.3 M | 31 M | 31 M | 31 M | 31 M | -32.2 M | -32.2 M | -32.2 M | -32.2 M | -25.3 M | - | - | - | -17.7 M | - | - | - | - | - | - | - |
All numbers in USD currency